Xenon Pharmaceuticals INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 10.3% in Xenon Pharmaceuticals Inc. common stock as of July 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 4,175,982 common shares, representing 4.5% of the class, in Xenon Pharmaceuticals Inc.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 6.26% of Xenon Pharmaceuticals, Inc. common shares as of March 31, 2026.

Driehaus Capital Management LLC has increased its beneficial ownership of Xenon Pharmaceuticals Inc. common stock to 4.87%, acquiring 4,491,653 shares.

Wellington Management Group and its affiliates have reported a 6.2% beneficial ownership stake in Xenon Pharmaceuticals Inc. as of December 31, 2025.

Janus Henderson Group plc has reported a 5.1% beneficial ownership stake in XENON PHARMACEUTICALS INC. common stock.

Wellington Management Group and its affiliates have disclosed a 2.8% passive ownership stake in Xenon Pharmaceuticals Inc. as of June 30, 2025.

FMR LLC and Abigail P. Johnson have reported an 11.5% beneficial ownership stake in XENON PHARMACEUTICALS INC common stock as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.2% of Xenon Pharmaceuticals Inc.'s Common Stock as of June 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a passive beneficial ownership of 10.3% in XENON PHARMACEUTICALS INC as of February 28, 2025.